Cipla Launches First Biosimilar of Etanercept in India for Rheumatic Disorders - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cipla Launches First Biosimilar of Etanercept in India for Rheumatic Disorders



Cipla has launched the first biosimilar of etanercept in India for the treatment of rheumatoid disorders. The product will be marketed under the brand name Etacept. The launch of Etacept marks Cipla's entry into the biologics market, offering a low-cost alternative to Pfizer and Amgen's rheumatic disorder blockbuster Enbrel in India.

"The higher cost of biologics has been a major hindrance, limiting its affordability and accessibility to millions of patients. We believe that introducing etacept at a lower cost (of 30% lesser as compared to the innovator) will enable access of this drug to a greater number of patients in India," commented Dr Jaideep Gogtay, medical director of Cipla in a company’s press release.

Etacept contains the biologic etanercept, which is produced by recombinant DNA technology. The product, manufactured by China's Shanghai CP Guojian Pharmaceutical Co. Ltd., is available as a lyophilized powder for subcutaneous injection. Since its launch in China by Shanghai CP Guojian Pharmaceutical Co. Ltd. in 2006, more than 50 000 patients have been treated with etanercept. According to Cipla, the drug has demonstrated clinical efficacy and safety in Indian patients. A recent study showed that for patients who were successfully treated with etanercept for 6 months, a 50% reduction in dose provided the same benefit as continuing with the current dose.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here